Headaches are one of the most common medical complaints, with up to 47% of adults experiencing them on a regular basis. While there are a variety of treatments available, some headaches remain mysterious and challenging to treat. Paroxysmal hemicrania (PH) is one such headache disorder, characterized by sudden, intense, and recurrent episodes of pain on one side of the head. Despite the fact that PH has been recognized for over 40 years, it remains a largely unexplored mystery in the field of headache treatment. This article will explore the current understanding of PH, its diagnosis, and potential treatments.
Paroxysmal hemicrania is a rare type of primary headache disorder, meaning it is not caused by an underlying medical condition. It was first described in 1976 by Dr. J.M. Sjaastad and colleagues. PH is characterized by sudden, intense, and recurrent episodes of pain on one side of the head. The pain is usually localized to the area around the eye, but can spread to the forehead, temple, and even the neck. The episodes of pain can last anywhere from a few seconds to several minutes, and can occur multiple times a day.
The diagnosis of PH is based on a combination of clinical history, physical examination, and laboratory tests. The diagnosis is made based on the presence of certain criteria, such as the presence of recurrent and unilateral attacks of severe, short-lasting pain, lasting from 5 seconds to 30 minutes. Other criteria include the presence of autonomic symptoms, such as tearing, redness, and nasal congestion, as well as the absence of any other causes of headache.
The treatment of PH is largely based on the use of medications. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce the frequency and intensity of the attacks. Other medications such as triptans, anticonvulsants, and calcium channel blockers may also be used. In addition, certain lifestyle modifications, such as avoiding triggers, can be helpful in managing the disorder.
Despite the fact that PH has been recognized for over 40 years, research into the disorder is still in its early stages. The mechanisms underlying the disorder are still largely unknown, and there is a lack of clinical studies to evaluate the efficacy of available treatments. Furthermore, the diagnosis of PH can be difficult, as it is often misdiagnosed as a migraine or cluster headache.
Paroxysmal hemicrania is a rare and mysterious primary headache disorder, characterized by sudden, intense, and recurrent episodes of pain on one side of the head. While there are treatments available, research into the disorder is still in its early stages, and the diagnosis can be difficult. As such, PH remains a largely unexplored mystery in the field of headache treatment. With further research, it is hoped that more effective treatments can be developed to help those who suffer from this disorder.
1.
In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
4.
A prostate cancer risk prediction algorithm could help target men at highest risk
5.
A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.
1.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
2.
Bone Marrow Regeneration in Hematologic Recovery
3.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
4.
Iron Homeostasis Throughout the Female Lifespan
5.
Demystifying Lymphocytes: Everything You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation